BioSpace News Archive

Helocyte, Inc. announced that data from a Phase 1 pilot study published in the American Journal of Hematology demonstrated the feasibility, safety, immunological response and potential efficacy associated with vaccination of a hematopoietic cell transplant donor with the cytomegalovirus vaccine Triplex to enhance protective CMV-specific T cells in immunosuppressed recipients of allogeneic HCT.

Renexxion Ireland Limited, a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, is pleased to announce that the first patient has been treated in Europe with naronapride, a potential best-in-class pan-GI prokinetic, in a Phase IIb trial for gastroparesis conducted by Dr. Falk Pharma GmbH (Dr. Falk Pharma).

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA) today announced top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware.

RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage radiopharmaceutical company announced the acquisition of it’s 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals.

Morphoceuticals Inc., a biotechnology company, announced it closed an $8 million Seed-2 funding round led by Prime Movers Lab and initial investor Juvenescence.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 43rd Annual Cowen Health Care Conference, to be held in Boston, Massachusetts on March 6-8th, 2023.

Alveolus Bio announced today that they have received a Small Business Innovation Research (SBIR) FastTrack grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).

Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.

Owens & Minor, Inc. plans to release financial results for the fourth quarter and full year of 2022 on Tuesday, February 28, 2023, before trading begins on the New York Stock Exchange.

GeoVax Labs, Inc. (Nasdaq: GOVX), and EmVenio Research today announced a collaboration to deploy a mobile clinical facility in the Claremont, California area to expand GeoVax’s ongoing Phase 2 clinical trial evaluating GEO-CM04S1 as a COVID-19 booster vaccine in healthy patients.